drugset / Trial / NCT05385510
Assessment of Safety and Immunogenicity of R21/Matrix-M™ in African Children Living With HIV
Phase 1
Completed
122 enrolled
University of Oxford
MRC/UVRI and LSHTM Uganda Research Unit · collab
Non-randomizedParallel-groupOpen-labelPrevention
Summary
A Phase Ib trial to evaluate the safety and immunogenicity of R21/Matrix-M™ in African children living with HIV
Timeline
- Start
- 2023-01-10
- Primary completion
- 2025-09-03
- Completion
- 2025-09-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Matrix-M1 Adjuvant | Other / unclassified | 5 ug | — |
| Subject | Matrix-M1 Adjuvant | Other / unclassified | 50 ug | — |